Key terms

About TNXP

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest TNXP news

Mar 25 9:12am ET Tonix Pharma Earns FDA Pediatric Designation Amid Risks Mar 25 8:25am ET Tonix Pharmaceuticals receives Rare Pediatric Disease designation for TNX-2900 Mar 21 9:33am ET Tonix Pharma Reveals Innovative Oxytocin Research Advancements Mar 21 8:15am ET Tonix Pharmaceuticals announces presentation at ACS of next-gen oxytocin Mar 20 10:02am ET Tonix Pharma Readies for Tonmya™ U.S. Launch and Production Mar 20 8:04am ET Tonix selects two contract manufacturing organizations for launch of Tonmya Mar 19 8:22am ET Tonix Pharma Announces Full Integration and Future Plans Mar 19 8:13am ET Tonix announces transition to fully integrated biopharmaceutical company Mar 11 8:23am ET Tonix Pharma’s Tonmya Shows Promise in Fibromyalgia Study Mar 11 8:08am ET Tonix Pharmaceuticals presents additional efficacy data from RESILIENT Mar 07 8:23am ET Tonix Pharma’s TNX-102 SL Shows Promise for PTSD Treatment Mar 07 8:18am ET Tonix Pharmaceuticals announces publication on TNX-102 SL Mar 06 8:22am ET Tonix Pharma: Anticipating Tonmya’s Impact on Fibromyalgia Treatment Mar 06 8:12am ET Tonix Pharmaceuticals selectes EVERSANA to support launch strategy of Tonmya Mar 05 8:22am ET Tonix announces translation of preclinical PK parameters of TNX-1500 Mar 05 8:22am ET Tonix Pharma Advances with Promising TNX-1500 Studies Feb 28 8:23am ET Tonix Pharma Advances TNX-1500 Trial, Cautions Investors Feb 28 8:04am ET Tonix Pharmaceuticals completes clinical stage of Phase 1 trial for TNX-1500 Feb 27 8:22am ET Tonix Pharma Expands Asian Market Reach with Tonmya™ Study Feb 27 8:18am ET Tonix Pharmaceuticals announces results from clinical PK study of Tonmya Feb 15 5:12pm ET Tonix Pharma Shareholders Approve Strategic Financing Moves Feb 15 11:05am ET Biotech Alert: Searches spiking for these stocks today Feb 14 11:08am ET Biotech Alert: Searches spiking for these stocks today Feb 14 8:24am ET Tonix Pharmaceuticals hosted KOL webinar on Phase 3 fibromyalgia trial Feb 13 8:22am ET Tonix Pharma Advances Tonmya™ with New FDA Application Partner Feb 12 8:19am ET Tonix Pharma Receives FDA Nod, Updates Investor Presentation Feb 12 8:04am ET Tonix Pharmaceuticals announces FDA IND clearance for trial of TNX-102 SL Jan 31 7:08am ET Tonix Pharmaceuticals announces research on pre-existing pain conditions, COVID Jan 26 4:28am ET Tonix Pharma Shareholders Approve Expansion of Shares Jan 26 4:27am ET Tonix Pharma Expands Authorized Stock Capacity Jan 09 7:08am ET Tonix Pharmaceuticals presents additional data from TNX-203 SL

No recent news articles are available for TNXP

No recent press releases are available for TNXP

TNXP Financials

1-year income & revenue

Key terms

TNXP Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

TNXP Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms